Jul 16, 2014
LOUVAIN-LA-NEUVE, BELGIUM, 16 July 2014 – IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has received Marketing Authorization from the U.S. Food and Drug Administration (FDA) for its Compact Gantry Beam Line (CGBL: FDA 510(k) K132919). IBA anticipates that this regulatory approval will intensify the international interest in Proteus®ONE*, IBA’s next generation proton therapy compact system.
Proteus®ONE is IBA’s single-room proton therapy system which is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including IBA’s Intensity Modulated Proton Therapy (IMPT). IBA created the Proteus®ONE system to allow more patients access to proton therapy globally and has already sold five Proteus®ONE systems in Shreveport, Louisiana (USA), Nice (France), Taiwan (China) and two in Japan.
Olivier Legrain, Chief Executive Officer of IBA commented: “We are delighted to have received Marketing Authorization from the FDA for the Proteus®ONE Compact Gantry. This is an exciting milestone for our customers in North America, where the cost of healthcare is a major focus. The Proteus®ONE aligns with the US healthcare trend of providing the highest quality of cancer treatment possible at the best possible price. We are confident that Proteus®ONE will drive greater momentum in the adoption of this next generation targeted cancer treatment internationally. The approval reaffirms our world leading position in the delivery of highly targeted, safer cancer treatment solutions. We very much look forward to the first patients at the Willis-Knighton Cancer Centre in the US benefitting from our compact proton therapy offering later this year.”
Lane R. Rosen, MD, Director of Radiation Oncology at the Willis-Knighton Cancer Centre, added: “We are very excited to have Intensity Modulated Proton Therapy become an available option for our patients. The complete clearance of the Proteus®ONE system, installed at Willis-Knighton, is yet another milestone demonstrating how IBA and WKCC partner for progress.” yet another milestone demonstrating how IBA and WKCC partner for progress.”
©
April 1, 2014
Varian and Paul Scherrer Institute extend proton therapy R&D collaboration
Apr 1, 2014
BERGISCH GLADBACH, GERMANY, 31 March 2014 – Varian Medical Systems (NYSE: VAR) and the Paul Scherrer Institute (PSI) are announcing an extension of their existing collaboration in the field of proton therapy to offer patients more precise cancer treatments using intensity modulated proton therapy (IMPT). Under the agreement, Varian will also supply technology and equipment to help meet a growing demand for clinical research and treatments at PSI.
Proton therapy targets tumors with concentrated doses of radiation while offering superior protection of surrounding healthy tissue. IMPT, which was pioneered using pencil-beam scanning at the Paul Scherrer Institute and made commercially available by Varian Medical Systems, is a radiation delivery technique that enables clinicians to optimize precision when treating tumors.
"This multi-year R&D collaboration will enable Varian and PSI to continue their productive research activities in the areas of advanced pencil beam scanning delivery systems, on-board imaging, clinical workflow optimization, and accelerator technology to further develop proton treatment technology over the coming years," says Moataz Karmalawy, head of Varian's Particle Therapy group. "Our original collaboration led to the commercialization of IMPT and we are delighted to expand our partnership to develop more revolutionary technologies."
"Over the past ten years we have developed scanning techniques for the treatment of tumors with intensity-modulated proton therapy," adds Prof. Dr. Joel Mesot, director of the Paul Scherrer Institute. "We are looking forward to the new collaboration as it will help us to develop more tools for treating more patients with even greater precision while making our technology more widely available to the clinical and scientific community."
The value of the equipment portion of the contract is approximately $10 million and it will be booked in the second quarter of fiscal 2014.
Varian's scanning beam IMPT technology is already being used at the Scripps Proton Therapy Center in San Diego, U.S., and the Rinecker Proton Therapy Center in Munich, Germany. Varian also has contracts to install ProBeam systems at six additional sites in the U.S., Saudi Arabia, and Russia.
*CE mark and international registrations pending for ProBeam. Not available for sale in all markets.
©
BERGISCH GLADBACH, GERMANY, 31 March 2014 – Varian Medical Systems (NYSE: VAR) and the Paul Scherrer Institute (PSI) are announcing an extension of their existing collaboration in the field of proton therapy to offer patients more precise cancer treatments using intensity modulated proton therapy (IMPT). Under the agreement, Varian will also supply technology and equipment to help meet a growing demand for clinical research and treatments at PSI.
Proton therapy targets tumors with concentrated doses of radiation while offering superior protection of surrounding healthy tissue. IMPT, which was pioneered using pencil-beam scanning at the Paul Scherrer Institute and made commercially available by Varian Medical Systems, is a radiation delivery technique that enables clinicians to optimize precision when treating tumors.
"This multi-year R&D collaboration will enable Varian and PSI to continue their productive research activities in the areas of advanced pencil beam scanning delivery systems, on-board imaging, clinical workflow optimization, and accelerator technology to further develop proton treatment technology over the coming years," says Moataz Karmalawy, head of Varian's Particle Therapy group. "Our original collaboration led to the commercialization of IMPT and we are delighted to expand our partnership to develop more revolutionary technologies."
"Over the past ten years we have developed scanning techniques for the treatment of tumors with intensity-modulated proton therapy," adds Prof. Dr. Joel Mesot, director of the Paul Scherrer Institute. "We are looking forward to the new collaboration as it will help us to develop more tools for treating more patients with even greater precision while making our technology more widely available to the clinical and scientific community."
The value of the equipment portion of the contract is approximately $10 million and it will be booked in the second quarter of fiscal 2014.
Varian's scanning beam IMPT technology is already being used at the Scripps Proton Therapy Center in San Diego, U.S., and the Rinecker Proton Therapy Center in Munich, Germany. Varian also has contracts to install ProBeam systems at six additional sites in the U.S., Saudi Arabia, and Russia.
*CE mark and international registrations pending for ProBeam. Not available for sale in all markets.
©
March 30, 2014
Radiance 330 proton therapy system to be installed at MGH
Flower Mound, TX, 27 March 2014 – ProTom International, Inc. ("ProTom") is pleased to announce the execution of a purchase agreement with Massachusetts General Hospital ("MGH") for the acquisition of a Radiance 330® Proton Therapy System ("Radiance 330") to be housed in the MGH Department of Radiation Oncology. Under the terms of the contract, ProTom will supply a single treatment room configuration including its compact 330 MeV synchrotron accelerator and 180-degree gantry with robotic patient positioner.
The Radiance 330 is equipped with ProTom's Fidelity™ Beam Scanning System, innovative technology designed and optimized for discrete scanning. This type of scanning accurately "paints" the tumor with the physician-prescribed proton dose using magnetic steering to guide lateral dose deposition and beam energy variations -- changed within a second, with sub-millimeter accuracy -- to control penetration depth. This highly sophisticated 3-dimensional beam scanning technique enables the physician to exploit the dose control advantages of protons to their full potential, even for the most complex cases.
At MGH the entire system will be installed inside a radiation-shielded vault embedded within the existing radiation oncology department -- a solution that enables the facility to share clinical staff, ancillary equipment, and patient support areas. The Radiance 330 synchrotron can be installed within an interior accelerator vault space of 20' x 30' and requires up to 40% less radiation shielding than many other systems on the market today. The lighter-weight, compact technology simplifies the installation process; and the largest component of any system configuration (fixed beam, 180 degree gantry, etc.) requires no special road transport, facility hatch, or extraordinary cranes and can be moved in through typical freight or staff entrances.
The design of the Radiance 330 allows health care providers to develop single or multiple-room capability within or adjacent to an existing radiation oncology department; and its beam transport design supports both horizontal and vertical beam lines to accommodate a multi-level layout where space constraints may dictate that treatment room(s) and the accelerator be located on different floors.
©
The Radiance 330 is equipped with ProTom's Fidelity™ Beam Scanning System, innovative technology designed and optimized for discrete scanning. This type of scanning accurately "paints" the tumor with the physician-prescribed proton dose using magnetic steering to guide lateral dose deposition and beam energy variations -- changed within a second, with sub-millimeter accuracy -- to control penetration depth. This highly sophisticated 3-dimensional beam scanning technique enables the physician to exploit the dose control advantages of protons to their full potential, even for the most complex cases.
At MGH the entire system will be installed inside a radiation-shielded vault embedded within the existing radiation oncology department -- a solution that enables the facility to share clinical staff, ancillary equipment, and patient support areas. The Radiance 330 synchrotron can be installed within an interior accelerator vault space of 20' x 30' and requires up to 40% less radiation shielding than many other systems on the market today. The lighter-weight, compact technology simplifies the installation process; and the largest component of any system configuration (fixed beam, 180 degree gantry, etc.) requires no special road transport, facility hatch, or extraordinary cranes and can be moved in through typical freight or staff entrances.
The design of the Radiance 330 allows health care providers to develop single or multiple-room capability within or adjacent to an existing radiation oncology department; and its beam transport design supports both horizontal and vertical beam lines to accommodate a multi-level layout where space constraints may dictate that treatment room(s) and the accelerator be located on different floors.
©
Subscribe to:
Posts (Atom)